Guggenheim on Spyre Therapeutics (NASDAQ: SYRE): 'remains one of our Top 2026 Picks'.The analyst comments "This morning, Spyre announced the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE